A new trading day began on Friday, with Cardiff Oncology Inc (NASDAQ: CRDF) stock price down -9.15% from the previous day of trading, before settling in for the closing price of $2.84. CRDF’s price has ranged from $1.03 to $6.42 over the past 52 weeks.
Here's Your FREE Report on the #1 Small-Cap Uranium Stock of '24.
Small-cap Uranium stocks are booming in 2024! The company we're about to show you is the ONLY small-cap stock in the space that benefits from ALL aspects of the global Uranium industry with none of the risks of running a mine. Smart investors will not be hesitating on this one!
Get the FREE Report with all the details here.
Sponsored
During the last 5-year period, the sales growth of Healthcare Sector giant was 9.26%. Meanwhile, its annual earnings per share averaged -7.10%. With a float of $47.17 million, this company’s outstanding shares have now reached $51.13 million.
Let’s determine the extent of company efficiency that accounts for 32 employees. In terms of profitability, gross margin is 55.01%, operating margin of -6735.99%, and the pretax margin is -6239.04%.
Cardiff Oncology Inc (CRDF) Insider Activity
As we move forward, let’s examine how large-scale investors are investing in this stock of the Biotechnology Industry. The insider ownership of Cardiff Oncology Inc is 7.76%, while institutional ownership is 24.91%. The most recent insider transaction that took place on Dec 19 ’23, was worth 41,100. In this transaction Director of this company bought 30,000 shares at a rate of $1.37, taking the stock ownership to the 697,761 shares.
Cardiff Oncology Inc (CRDF) Earnings and Forecasts
According to the Wall Street analysts, stocks earnings will be around -7.10% per share during the next fiscal year.
Cardiff Oncology Inc (NASDAQ: CRDF) Trading Performance Indicators
Here are Cardiff Oncology Inc’s current performance indicators. According to the last quarter’s results, the stock had a quick ratio of 4.74. In addition, a publicly-traded company’s price to sales ratio for the trailing twelve months stands at 173.70.
For the trailing twelve months, Company’s Diluted EPS (Earnings per Share) is -0.95, a number that is poised to hit -0.25 in the next quarter and is forecasted to reach -0.98 in one year’s time.
Technical Analysis of Cardiff Oncology Inc (CRDF)
Looking closely at Cardiff Oncology Inc (NASDAQ: CRDF), its last 5-days average volume was 0.95 million, which is a drop from its year-to-date volume of 0.95 million. As of the previous 9 days, the stock’s Stochastic %D was 4.36%. Additionally, its Average True Range was 0.36.
During the past 100 days, Cardiff Oncology Inc’s (CRDF) raw stochastic average was set at 24.05%, which indicates a significant increase from 2.70% during the past two weeks. Based on volatility metrics of the stock, it showed a historical volatility of 163.50% in the past 14 days, which was higher than the 89.34% volatility it showed in the past 100 days.
At the time of writing, stock’s 50-day Moving Average is $2.82, while its 200-day Moving Average is $3.08. However, in the short run, Cardiff Oncology Inc’s stock first resistance to watch stands at $2.80. Second resistance stands at $3.01. The third major resistance level sits at $3.15. If the price goes on to break the first support level at $2.45, it is likely to go to the next support level at $2.31. Should the price break the second support level, the third support level stands at $2.10.
Cardiff Oncology Inc (NASDAQ: CRDF) Key Stats
With a market capitalization of 119.85 million, the company has a total of 51,134K Shares Outstanding. Currently, annual sales are 490 K while annual income is -41,440 K. The company’s previous quarter sales were 170 K while its latest quarter income was -11,860 K.
